Immunovant, Inc.
A clinical-stage biopharmaceutical company developing experimental antibody medicines for autoimmune diseases, where the body's own defenses attack healthy tissue. Its drug candidates, like batoclimab, work by lowering the harmful antibodies that drive these conditions. Immunovant was founded in 2018 within the Roivant Sciences family and went public in 2019 through a merger. Its name blends "immuno," for immunology, with the "-vant" suffix that Roivant gives all its specialized subsidiaries.
Granted 4.47M · Bought 35.45M
Granted 1.12M · Sold 646.4K
Granted 941.6K · Bought 20.0K
Granted 268.0K · Sold 171.8K
Granted 546.8K · Sold 150.1K
Granted 367.6K · Sold 122.3K
Granted 398.5K · Sold 79.2K
Granted 283.4K · Sold 35.8K
Granted 601.0K · Sold 14.2K
Granted 269.8K · Sold 48.5K
Granted 298.1K · Sold 86.4K
Granted 156.6K · Sold 38.6K
Granted 219.9K · Sold 39.3K
Granted 82.8K · Sold 12.7K
Granted 105.6K · Bought 15.0K · Sold 29.1K
Granted 96.6K · Sold 20.4K
Granted 293.2K · Sold 264.6K
Granted 38.9K
Granted 38.9K · Sold 2.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Roivant Sciences Ltd.Director, 10% owner · 5 transactions | +54.4% | 113.32M | 4.47M | 35.45M | — |
| Salzmann PeterChief Executive Officer, Director · 45 transactions | +67.6% | 1.18Mas of Apr 2025 | 1.12M | — | 646.4K |
| Torti FrankDirector · 7 transactions | +2020.2% | 1.01M | 941.6K | 20.0K | — |
| Butchko Julia G.Chief Development Officer · 33 transactions | +27.9% | 441.1Kas of Aug 2024 | 268.0K | — | 171.8K |
| Barnett Eva ReneeChief Financial Officer · 39 transactions | — | 396.8Kas of Apr 2025 | 546.8K | — | 150.1K |
| Macias William L.Chief Medical Officer · 39 transactions | +218.9% | 357.4Kas of Feb 2025 | 367.6K | — | 122.3K |
| Levine Mark S.Chief Legal Officer · 27 transactions | — | 319.2Kas of Nov 2024 | 398.5K | — | 79.2K |
| Girao TiagoChief Financial Officer · 5 transactions | — | 257.6K | 283.4K | — | 35.8K |
| Venker EricChief Executive Officer, Director · 5 transactions | — | 251.8K | 601.0K | — | 14.2K |
| Gloria MelanieChief Operating Officer · 15 transactions | — | 219.3K | 269.8K | — | 48.5K |
| Stout Jay SChief Technology Officer · 22 transactions | — | 218.4K | 298.1K | — | 86.4K |
| Geffner MichaelChief Medical Officer · 14 transactions | — | 218.0K | 156.6K | — | 38.6K |
| Van Tuyl ChristopherChief Legal Officer · 11 transactions | — | 198.4K | 219.9K | — | 39.3K |
| Migausky George VDirector · 8 transactions | +104.2% | 137.3Kas of Apr 2025 | 82.8K | — | 12.7K |
| Pande AtulDirector · 17 transactions | — | 136.7K | 105.6K | 15.0K | 29.1K |
| Hughes Douglas J.Director · 9 transactions | +130.4% | 134.7K | 96.6K | — | 20.4K |
| Fromkin Andrew J.Director · 19 transactions | +187.5% | 131.4K | 293.2K | — | 264.6K |
| Bauer JakeDirector · 2 transactions | — | 38.9K | 38.9K | — | — |
| Susman Robert GrahamDirector · 3 transactions | — | 36.4K | 38.9K | — | 2.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +33.73M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.